ArticlePLoS medicine2026
Plasma proteomic signatures of subclinical atherosclerosis progression for cardiovascular risk stratification: A cohort study.
Article in PLoS medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Seeing the invisible: Reorienting cardiovascular risk prediction across the disease trajectory.PLoS medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundExisting risk stratification tools inadequately identify individuals with subclinical atherosclerosis (SA) who could benefit from early intervention. This study aimed to develop protein risk scores (ProtRSs) for SA progression and assess their incremental value for atherosclerotic cardiovascular disease (ASCVD) risk prediction. METHODS AND
findingsIn a community cohort consisting of 903 individuals undergoing repeated SA assessments (coronary artery calcium [CAC] or carotid plaque) over 6 years (2008-2009 to 2013-2014), protein biomarkers were selected from a panel of 117 proteins using least absolute shrinkage and selection operator (LASSO) regression to construct SA ProtRSs for CAC and plaque progression, respectively, and their predictive abilities for incident ASCVD risk were evaluated based on a guideline-recommended traditional risk score in a case-cohort of 1,835 individuals (2007-2008 to 2018-2021, median follow-up of 10.4 years). The ProtRSs each included 14 proteins for CAC and plaque progression, explaining 17.1% and 18.4% of respective variances. Effect sizes of these proteins on SA progression showed strong concordance with those on incident ASCVD (r > 0.75). Each standard deviation increase in CAC and plaque ProtRSs was associated with hazard ratios of 1.36 (95% confidence interval [CI] [1.20,1.54]) and 1.38 (95% CI [1.23,1.54]) for ASCVD risk, respectively. Addition of the SA ProtRSs to the traditional risk score yielded a net reclassification improvement of 0.127 (p < 0.001). Importantly, 18.6% of traditional intermediate-risk individuals were reclassified into the high-risk category (10-year ASCVD event rate: 10.9%), indicating the need for preventive interventions, whereas 32.8% of traditional high-risk individuals were identified as having an even higher rate (13.7%), suggesting the requirement for intensified management. The main limitation is that the predictive value of ProtRSs warrants further large-scale external validation.
conclusionsSA ProtRSs of coronary calcification and carotid plaque progression may provide additional value over traditional risk assessment, highlighting their potential in refining risk stratification and guiding targeted intervention strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.